## Correspondence

# Comment on: Post surgical hypoparathyroidism

### To the Editor

We welcome the comprehensive review by Alqahtani on post-thyroidectomy hypoparathyroidism. Measuring plasma parathormone (PTH) level within 12-24 hours after total thyroidectomy may predict which patients will not develop permanent hypoparathyroidism after 6 to 12 months. If plasma PTH value is higher than 1.05 pmol/L (10 pmol/mL) 12 to 24 hours postsurgery, the development of hypoparathyroidism is unlikely. But if the plasma PTH level is lower than 1.05 pmol/L (10pmol/mL), the possibility of longterm hypoparathyroidism remains but is less than 50%. However, a significant number of patients with PTH values <1.05 pmol/L (10 pmol/mL) 12–24 hours post-thyroidectomy may still recover from temporary hypoparathyroidism.<sup>2</sup>

New guidelines for managing hypoparathyroidism were published in 2022.<sup>3</sup> Conventional therapy includes the use of calcium carbonate or citrate with either cholecalciferol (vitamin D3) or ergocalciferol (vitamin D2) or an active form of vitamin D (calcitriol or alfacalcidol). Thiazide diuretics may also be considered.<sup>3</sup> If serum calcium (albumin adjusted) and serum phosphate cannot be normalized, PTH-based therapies, palopegteriparatide and teriparatide have to be considered.

Patients need to be informed of the symptoms of hypocalcaemia prior to discharge. It is good practice to arrange an US examination of the kidneys (to exclude nephrocalcinosis), eye examination for cataract and DXA scan in postmenopausal women (to assess bone mineral density) a year after surgery.

> Ali S. Jawad Department of Rheumatology Royal London Hospital United Kingdom

Saudi Med J 2025; Vol. 46 (1): 107 doi: 10.15537/smj.2025.46.1.20241114

#### Reply from the Author

No reply was received from the Author.

### References

- Alqahtani SM. Post-thyroidectomy hypoparathyroidism. Saudi Med J 2024; 45: 1305-1311.
- Clarke BL. Hypoparathyroidism: update of guidelines from the 2022 International Task Force. *Arch Endocrinol Metab* 2022; 66: 604-610.
- 3. Khan AA, Bilezikian JP, Brandi ML, Clarke BL, Gittoes NJ, Pasieka JL et al. Evaluation and management of hypoparathyroidism summary statement and guidelines from the second international workshop. *J Bone Miner Res* 2022; 37: 2568-2585.